Gilead Sciences, Inc. (GILD) Comparison with companies in other sectors?

Gilead Sciences, Inc. has a share price of 1.24B. You can analyze Gilead Sciences, Inc. (GILD) competitors across different market sectors through stock heatmaps.

What are GILD's NET and operating margins?

Gilead Sciences, Inc. (GILD) operating margin is around 0.29, and net profit margin is approximately 0.21 as of the latest reports.

In what way does GILD's earnings per share (EPS) trend reflect its financial momentum?

Gilead Sciences, Inc. (GILD) EPS is 7.74 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for Gilead Sciences, Inc. is 15.01, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for Gilead Sciences, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for Gilead Sciences, Inc. like P/E which is 24.30, P/B which is 7.57, and PEG which is 0.02. Compare them with sector averages to evaluate if the stock is priced fairly.

Gilead Sciences, Inc.

GILD•NASDAQ

Healthcare

Drug Manufacturers - General

$116.20

$3.00(2.65%)

Fundamental Analysis of Gilead Sciences, Inc. (GILD)

Comprehensive financial metrics and ratios analysis

EPS (TTM)

$7.74

P/E Ratio

15.01

ROE

0.32%

Net Margin

0.21%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$144.54B

Shares OutstandingTotal number of shares issued

$1.24B

Book Value/ShareNet worth per share

$15.31

Revenue/ShareAnnual revenue per share

$23.06

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$7.74

Net MarginNet income as percentage of revenue

20.76%

Operating MarginOperating income as percentage of revenue

28.61%

ROEReturn on shareholders' equity

31.71%

ROAReturn on total assets

10.57%

ROCEReturn on capital employed

18.65%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

$7.90

Cash/ShareCash and equivalents per share

$6.36

FCF YieldFree cash flow as percentage of market cap

6.78%

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

$3.12

Dividend YieldAnnual dividend as percentage of stock price

2.67%

Financial Ratios Analysis data is not available for GILDFinancial Ratios Analysis details for GILD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for GILDSector Benchmarking details for GILD are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for Gilead Sciences, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of Gilead Sciences, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account Gilead Sciences, Inc.'s unique business strengths and challenges.

Key Financial Metrics for Gilead Sciences, Inc.

For Gilead Sciences, Inc., essential financial indicators include EPS 7.74, PE 15.01, and ROE 0.32. These key ratios reveal insights into Gilead Sciences, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare Gilead Sciences, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of Gilead Sciences, Inc.

Metrics like Net Margin 20.76% and ROA 10.57% shed light on how well Gilead Sciences, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether Gilead Sciences, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of Gilead Sciences, Inc.

Using ratios such as P/B Ratio 7.57 and PEG Ratio 0.02, investors can assess whether Gilead Sciences, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with Gilead Sciences, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for Gilead Sciences, Inc.

Financial health indicators, such as Debt/Equity Ratio 1.30 and Cash Flow $7.90, provide a snapshot of Gilead Sciences, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like Gilead Sciences, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for Gilead Sciences, Inc.

Investing in Gilead Sciences, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at Gilead Sciences, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;